
内科理论与实践››2022,Vol. 17››Issue (01): 43-47.doi:10.16138/j.1673-6087.2022.01.008
鲁晓岚, 夏巧云
收稿日期:2021-11-21出版日期:2022-02-28发布日期:2022-07-25基金资助:
Received:2021-11-21Online:2022-02-28Published:2022-07-25| [1] | Trivella J, Levy C. Safety considerations for the management of cholestatic itch[J]. Expert Opin Drug Saf, 2021, 20(8): 915-924. doi:10.1080/14740338.2021.1915984URL |
| [2] | Lieu T, Jayaweera G, Zhao P, et al. The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice[J]. Gastroenterology, 2014, 147(6): 1417-1428. doi:10.1053/j.gastro.2014.08.042URL |
| [3] | Yu H, Zhao T, Liu S, et al. MRGPRX4 is a bile acid receptor for human cholestatic itch[J]. Elife, 2019, 8: e48431. doi:10.7554/eLife.48431URL |
| [4] | Cipriani S, Renga B, D’Amore C, et al. Impaired itching perception in murine models of cholestasis is supported by dysregulation of GPBAR1 signaling[J]. PLoS One, 2015, 10(7): e0129866. doi:10.1371/journal.pone.0129866URL |
| [5] | Yu H, Wangensteen K, Deng T, et al. MRGPRX4 in cholestatic pruritus[J]. Semin Liver Dis, 2021, 41(3): 358-367. doi:10.1055/s-0041-1730923URL |
| [6] | Meixiong J, Vasavda C, Green D, et al. Identification of a bilirubin receptor that may mediate a component of cholestatic itch[J]. Elife, 2019, 8: e44116. doi:10.7554/eLife.44116URL |
| [7] | Patel SP, Vasavda C, Ho B, et al. Cholestatic pruritus: emerging mechanisms and therapeutics[J]. J Am Acad Dermatol, 2019, 81(6): 1371-1378. doi:10.1016/j.jaad.2019.04.035URL |
| [8] | Kittaka H, Uchida K, Fukuta N, et al. Lysophosphatidic acid-induced itch is mediated by signalling of LPA5 receptor, phospholipase D and TRPA1/TRPV1[J]. J Physiol, 2017, 595(8): 2681-2698. doi:10.1113/JP273961URL |
| [9] | Tian B, Wang XL, Huang Y, et al. Peripheral and spinal 5-HT receptors participate in cholestatic itch and antinociception induced by bile duct ligation in rats[J]. Sci Rep, 2016, 6: 36286. doi:10.1038/srep36286pmid:27824106 |
| [10] | Ostadhadi S, Kordjazy N, Haj-Mirzaian A, et al. 5-HT3 receptors antagonists reduce serotonin-induced scratching in mice[J]. Fundam Clin Pharmacol, 2015, 29(3): 310-315. doi:10.1111/fcp.12112URL |
| [11] | Shimizu K, Andoh T, Yoshihisa Y, et al. Histamine released from epidermal keratinocytes plays a role in α-melanocyte-stimulating hormone-induced itching in mice[J]. Am J Pathol, 2015, 185(11): 3003-3010. doi:10.1016/j.ajpath.2015.07.015pmid:26358220 |
| [12] | Andoh T, Suzuki K, Konno M, et al. Pharmacological characterization of a novel mouse model of cholestatic pruritus[J]. Biol Pharm Bull, 2020, 43(7): 1111-1117. doi:10.1248/bpb.b20-00097URL |
| [13] | Bergasa NV. The pruritus of cholestasis: from bile acids to opiate agonists: Relevant after all these years[J]. Med Hypotheses, 2018, 110: 86-89. doi:S0306-9877(17)31112-Xpmid:29317077 |
| [14] | Moniaga CS, Iwamoto S, Kitamura T, et al. Plasma dynorphin a concentration reflects the degree of pruritus in chronic liver disease[J]. Acta Derm Venereol, 2019, 99(4): 442-443. doi:10.2340/00015555-3139URL |
| [15] | Kumada H, Miyakawa H, Muramatsu T, et al. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial[J]. Hepatol Res, 2017, 47(10): 972-982. doi:10.1111/hepr.12830URL |
| [16] | Düll MM, Wolf K, Vetter M, et al. Endogenous opioid levels do not correlate with itch intensity and therapeutic interventions in hepatic pruritus[J]. Front Med (Lausanne), 2021, 8: 641163. |
| [17] | Wang Q, Hao C, Yao W, et al. Intestinal flora imbalance affects bile acid metabolism and is associated with gallstone formation[J]. BMC Gastroenterol, 2020, 20(1): 59. doi:10.1186/s12876-020-01195-1URL |
| [18] | Kitahata S, Yamamoto Y, Yoshida O, et al. Ileal mucosa-associated microbiota overgrowth associated with pathogenesis of primary biliary cholangitis[J]. Sci Rep, 2021, 11(1): 19705. doi:10.1038/s41598-021-99314-9pmid:34611265 |
| [19] | Rossen NG, Fuentes S, Boonstra K, et al. The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured clostridiales Ⅱ[J]. J Crohns Colitis, 2015, 9(4): 342-348. doi:10.1093/ecco-jcc/jju023URL |
| [20] | Zhan Q, Qi X, Weng R, et al. Alterations of the human gut microbiota in intrahepatic cholestasis of pregnancy[J]. Front Cell Infect Microbiol, 2021, 11: 635680. doi:10.3389/fcimb.2021.635680URL |
| [21] | Ji SG, Juran BD, Mucha S, et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease[J]. Nat Genet, 2017, 49(2): 269-273. doi:10.1038/ng.3745URL |
| [22] | Kim MJ, Kim JY, Kang M, et al. Reduced fecal calprotectin and inflammation in a murine model of atopic dermatitis following probiotic treatment[J]. Int J Mol Sci, 2020, 21(11): 3968. doi:10.3390/ijms21113968URL |
| [23] | Kim IS, Lee SH, Kwon YM, et al. Oral administration of β-glucan and lactobacillus plantarum alleviates atopic dermatitis-like symptoms[J]. J Microbiol Biotechnol, 2019, 29(11): 1693-1706. doi:10.4014/jmb.1907.07011URL |
| [24] | Sanjel B, Shim WS. Recent advances in understanding the molecular mechanisms of cholestatic pruritus[J]. Biochim Biophys Acta Mol Basis Dis, 2020, 1866(12): 165958. doi:10.1016/j.bbadis.2020.165958URL |
| [25] | De Vloo C, Nevens F. Cholestatic pruritus: an update[J]. Acta Gastroenterol Belg, 2019, 82(1): 75-82. |
| [26] | Ahmadi AR, Chicco M, van den Berge M. Rifampicin for treatment of cholestatic pruritus caused by drug-induced acute liver injury as assessed by the RUCAM classification[J]. Case Reports Hepatol, 2020, 2020: 8872804. |
| [27] | Webb GJ, Rahman SR, Levy C, et al. Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study[J]. Aliment Pharmacol Ther, 2018, 47(8): 1213-1219. doi:10.1111/apt.14579URL |
| [28] | Murray-Brown FL. Naltrexone for cholestatic itch: a systematic review[J]. BMJ Support Palliat Care, 2021, 11(2): 217-225. doi:10.1136/bmjspcare-2020-002801URL |
| [29] | European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol, 2017, 67(1): 145-172. doi:10.1016/j.jhep.2017.03.022URL |
| [30] | Thébaut A, Habes D, Gottrand F, et al. Sertraline as an additional treatment for cholestatic pruritus in children[J]. J Pediatr Gastroenterol Nutr, 2017, 64(3): 431-435. doi:10.1097/MPG.0000000000001385URL |
| [31] | Ovadia C, Lövgren-Sandblom A, Edwards LA, et al. Therapeutic plasma exchange as a novel treatment for severe intrahepatic cholestasis of pregnancy: case series and mechanism of action[J]. J Clin Apher, 2018, 33(6): 638-644. doi:10.1002/jca.21654URL |
| [32] | Chkheidze R, Joseph R, Burner J, et al. Plasma exchange for the management of refractory pruritus of cholestasis: a report of three cases and review of literature[J]. J Clin Apher, 2018, 33(3): 412-418. doi:10.1002/jca.21573pmid:28792089 |
| [33] | Pantzaris ND, Lord T, Sotheran R, et al. Nasobiliary drain diverted through a percutaneous endoscopic gastrostomy tube[J]. Case Rep Gastroenterol, 2021, 15(3): 891-897. doi:10.1159/000518057URL |
| [34] | Hussain AB, Samuel R, Hegade VS, et al. Pruritus secondary to primary biliary cholangitis: a review of the pathophysiology and management with phototherapy[J]. Br J Dermatol, 2019, 181(6): 1138-1145. doi:10.1111/bjd.17933pmid:30920648 |
| [35] | Ziogas IA, Alexopoulos SP, Matsuoka LK, et al. Livingvsdeceased donor liver transplantation in cholestatic liver disease: an analysis of the OPTN database[J]. Clin Transplant, 2020, 34(10): e14031. |
| [36] | Hegade VS, Kendrick SF, Dobbins RL, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study[J]. Lancet, 2017, 389(10074): 1114-1123. doi:S0140-6736(17)30319-7pmid:28187915 |
| [37] | Al-Dury S, Wahlström A, Wahlin S, et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis[J]. Sci Rep, 2018, 8(1): 6658. doi:10.1038/s41598-018-25214-0pmid:29704003 |
| [1] | 陆文婷 陈萍 卞薇薇.冷敷面膜在激光治疗后疼痛护理中的作用[J]. 组织工程与重建外科杂志, 2022, 18(4): 342-. |
| [2] | 陈佳佳 高敏哲 汪立 韩凌华 吴顺军 刘宁飞.妇科相关肿瘤术后下肢淋巴水肿合并会阴部水肿的综合治疗初探[J]. 组织工程与重建外科杂志, 2022, 18(3): 242-. |
| [3] | 戈成旺 林崴仪 唐枭伟 李磊 宋辉 蔡薇 沈干.鼻翼退缩的研究进展[J]. 组织工程与重建外科杂志, 2022, 18(3): 284-. |
| [4] | 聂萍 叶启程 王乐之 朱敏 王旭东.从唇腭裂序列治疗理念的角度探讨医学生人文关怀意识的培养[J]. 组织工程与重建外科杂志, 2022, 18(3): 286-. |
| [5] | 冯秋实.胆总管结石的微创治疗[J]. 外科理论与实践, 2022, 27(3): 185-188. |
| [6] | 陈胜.三镜联合微创治疗胆囊结石合并胆总管结石的方案选择[J]. 外科理论与实践, 2022, 27(3): 198-202. |
| [7] | 宣呈杰, 卞冬生, 蒋咏梅, 陈宇菲, 金佳斌, 施咏梅.营养治疗对减重术后身体成分及静息能量消耗的影响[J]. 外科理论与实践, 2022, 27(3): 244-248. |
| [8] | 许梓枫, 宗雅萍, 陆爱国.局部进展期结肠癌病人的新辅助治疗[J]. 外科理论与实践, 2022, 27(3): 266-270. |
| [9] | 陈承坤, 郭伯敏, 邓先兆, 伍波, 樊友本.甲状腺髓样癌的诊治现状[J]. 外科理论与实践, 2022, 27(3): 276-280. |
| [10] | 俞沁圆 王思圆 仲荣洲 李喆 黄国懂 魏雅洁 王斌.先天性多发手部关节挛缩支具治疗的临床评价[J]. 组织工程与重建外科杂志, 2022, 18(2): 144-. |
| [11] | 许佳 樊佳俊 韩冬 李馨 马燕红.增生性瘢痕压力治疗的研究进展[J]. 组织工程与重建外科杂志, 2022, 18(2): 176-. |
| [12] | 王小点 崔春晓 夏亮 冯少清 喜雯婧 肖文天 孟心娴 韩承尧 李科 章一新.远红外线治疗妇科癌症术后下肢淋巴水肿的安全性研究[J]. 组织工程与重建外科杂志, 2022, 18(1): 19-. |
| [13] | 汪立 刘宁飞 陈佳佳 高敏哲 韩凌华.肢体慢性淋巴水肿CDT治疗后低弹力绷带使用时长对远期疗效的影响[J]. 组织工程与重建外科杂志, 2022, 18(1): 25-. |
| [14] | 黄成 胡学庆.淋巴水肿治疗的研究进展[J]. 组织工程与重建外科杂志, 2022, 18(1): 38-. |
| [15] | 吴一文 王珊珊 张吕亚 肖喻 林洁 易庆阳 方木平 .红蓝光照射联合阿达帕林凝胶治疗轻、中度痤疮[J]. 组织工程与重建外科杂志, 2022, 18(1): 74-. |
| 阅读次数 | ||||||
| 全文 |
|
|||||
| 摘要 |
|
|||||